** Divi's Laboratories DIVI.NS shares climb 2% to 7,030 rupees
** Top gainer on pharma index .NIPHARM, which is trading 0.4% lower
** HSBC Global Research upgrades stock to "buy" from "reduce"
** HSBC lifts PT to 7,900 rupee from 5,020 rupees, highest on the Street among 24 analysts, per data complied by LSEG
** Notes "long runway of growth" for DIVI led by strong demand for weight-loss drug tirzeptide, the active ingredient in Eli Lilly's LLY.N Mounjaro
** Expects revenue potential of $450 mln for DIVI from peptides such as GLP-1s by 2030
** Avg rating on DIVI is "hold"; median PT 6,460 rupees - data compiled by LSEG
** DIVI best YTD performer on 20-member pharma index with 15% climb
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))